戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 aken in any patient with presumed idiopathic inflammatory myopathy.
2 ntrolled therapeutic trials in patients with inflammatory myopathy.
3 ggests an approach to treating patients with inflammatory myopathy.
4 lled therapeutic trials in all patients with inflammatory myopathy.
5 lin-dependent diabetes mellitus, and chronic inflammatory myopathy.
6 atomyositis are three distinct categories of inflammatory myopathy.
7 dentified in 1997 as a subtype of idiopathic inflammatory myopathy.
8 n as Jo-1) in the pathogenesis of idiopathic inflammatory myopathy.
9 lammation that is the hallmark of idiopathic inflammatory myopathy.
10 omyositis, the most common form of childhood inflammatory myopathy.
11 rial CMAS scores of children with idiopathic inflammatory myopathies.
12 o provide an update on the major advances in inflammatory myopathies.
13 r advances in clinical research on pediatric inflammatory myopathies.
14 les, and their reexpression is a hallmark of inflammatory myopathies.
15  same treatments that are effective in other inflammatory myopathies.
16 n the currently used designation, idiopathic inflammatory myopathies.
17 scle involvement in patients with idiopathic inflammatory myopathies.
18 th and endurance in children with idiopathic inflammatory myopathies.
19 nd help to clarify the pathogenesis of human inflammatory myopathies.
20 age and other pathologic features resembling inflammatory myopathies.
21 ning prognostic stratification in idiopathic inflammatory myopathies.
22 was rarely seen in those of other idiopathic inflammatory myopathies.
23 hold promise for the treatment of idiopathic inflammatory myopathies.
24 sted as specific markers for sIBM over other inflammatory myopathies.
25 ers are distinct from adult-onset idiopathic inflammatory myopathies.
26 systemic sclerosis, vasculitis or idiopathic inflammatory myopathies.
27 s, is important for the correct diagnosis of inflammatory myopathies.
28 al utility in distinguishing sIBM from other inflammatory myopathies.
29 ritic cells in the cause and pathogenesis of inflammatory myopathies.
30 for the maintenance of autoimmune lesions in inflammatory myopathies.
31 uld potentially play a role in certain human inflammatory myopathies.
32 characterizing, and monitoring treatment for inflammatory myopathies.
33 mechanisms in the pathogenesis of idiopathic inflammatory myopathies.
34  design of clinical trials in the idiopathic inflammatory myopathies.
35 pment of better therapies for the idiopathic inflammatory myopathies.
36 xpression at sites of muscle regeneration in inflammatory myopathies.
37 ons sufficient for an autoimmune response in inflammatory myopathies.
38 was an early and consistent feature of human inflammatory myopathies.
39 ignificance of non-immunological features of inflammatory myopathies.
40 non-immunological factors promote idiopathic inflammatory myopathies.
41 important information in the pathogenesis of inflammatory myopathies.
42 ses and clinical syndromes in the idiopathic inflammatory myopathies.
43                    Of 36 patients with other inflammatory myopathies, 1 patient had faint MxA stainin
44 y muscle specimens from 67 patients, 54 with inflammatory myopathies, 14 with dermatomyositis.
45 IEW: To review the treatment advances of the inflammatory myopathies, a heterogeneous group of diseas
46 age leading to regeneration may promote some inflammatory myopathies, although much remains to be lea
47                                   Similar to inflammatory myopathies, amyloid myopathy presents with
48 ized by muscle wasting and weakness, such as inflammatory myopathies and AIDS wasting.
49         The striking association between the inflammatory myopathies and anti-ARS antibodies implies
50 igate TWEAK-Fn14 expression in IBM and other inflammatory myopathies and explore whether TWEAK modula
51 ave become pivotal biomarkers for idiopathic inflammatory myopathies and have revolutionized understa
52 lex class I expression is highly specific to inflammatory myopathies and may be of diagnostic value.
53 scle of patients with mitochondrial disease, inflammatory myopathies and sarcopenia.
54 isease activity and damage in the idiopathic inflammatory myopathies and speculates on possibly usefu
55       The association between the idiopathic inflammatory myopathies and the development of malignanc
56 topathologic overlap between the features of inflammatory myopathies and those of other muscle disord
57 identified consecutively over 12 years, with inflammatory myopathies and weakness that was most sever
58     Inclusion body myositis is an idiopathic inflammatory myopathy and the most common myopathy affec
59  is applied to data sets involving diabetes, inflammatory myopathies, and Alzheimer's disease, using
60  expressed autoantigens typically present in inflammatory myopathies, and autoantigen expression incr
61 ing consequence of various chronic diseases, inflammatory myopathies, and neuromuscular disorders.
62   Autoantibodies may be found in humans with inflammatory myopathies, and these play an important rol
63 ar whether it should be considered a primary inflammatory myopathy, and it generally responds poorly
64 ctromyographic and muscle biopsy findings of inflammatory myopathy, and the typical skin rash of derm
65 his large series of patients with idiopathic inflammatory myopathy, anti-Jo-1 antibody levels correla
66                                              Inflammatory myopathies are a group of autoimmune diseas
67                                   Idiopathic inflammatory myopathies are a group of immune-mediated d
68                               The idiopathic inflammatory myopathies are an important and treatable g
69 ents pertaining to disease mechanisms in the inflammatory myopathies are discussed, emphasizing those
70                               The idiopathic inflammatory myopathies are diseases that can be difficu
71 h as the clinical features of the idiopathic inflammatory myopathies are not easily differentiated fr
72                   In humans, the most common inflammatory myopathies are polymyositis, dermatomyositi
73                                          The inflammatory myopathies are putative autoimmune disorder
74 o distinguish dermatomyositis from the other inflammatory myopathies, as well as from other myopathie
75       The features of these brachio-cervical inflammatory myopathy (BCIM) syndromes were compared wit
76 ogy (IM-EP), illustrated by brachio-cervical inflammatory myopathy (BCIM); histiocytic inflammatory m
77 eroids are the first line of therapy for the inflammatory myopathies, but because of their side effec
78 itors are being used to treat the idiopathic inflammatory myopathies, but their efficacy has not yet
79  as potential etiologic agents of idiopathic inflammatory myopathy, but their relationship to human m
80       Diseases that may mimic the idiopathic inflammatory myopathies can be differentiated more accur
81                                   Idiopathic inflammatory myopathies can significantly impair physica
82 expression is uniquely associated with human inflammatory myopathies characterized by hyperactive int
83 poradic inclusion body myositis (sIBM) is an inflammatory myopathy characterized by both degenerative
84          Inclusion body myositis (IBM) is an inflammatory myopathy characterized immunohistologically
85 kievirus B1 Tucson (CVB1(T)) develop chronic inflammatory myopathy (CIM) consisting of hind limb weak
86 om the muscle of mice afflicted with chronic inflammatory myopathy (CIM) was characterized and compar
87                                          The inflammatory myopathies, commonly described as idiopathi
88 y (IMNM) is considered one of the idiopathic inflammatory myopathies, comprising dermatomyositis, pol
89 enesis and course of the juvenile idiopathic inflammatory myopathies continued this year.
90 m of injury and death of muscle cells in the inflammatory myopathies (dermatomyositis, polymyositis,
91               The major syndromes of chronic inflammatory myopathy (dermatomyositis and polymyositis)
92                                Women in whom inflammatory myopathy develops after they receive silico
93 sts, different from mesoangioblasts in other inflammatory myopathies, display a myogenic differentiat
94                                          All inflammatory myopathies displayed overexpression of dege
95 itis, polymyositis, and the other idiopathic inflammatory myopathies focus primarily on features of m
96  identification of new cells and pathways in inflammatory myopathies has led to deeper mechanistic un
97  development of therapies for the idiopathic inflammatory myopathies have been enabled by recent prog
98 w classification criteria for the idiopathic inflammatory myopathies have been proposed in an effort
99 possible infectious causes of the idiopathic inflammatory myopathies have focused on retroviruses, in
100 anding of the pathogenesis of the idiopathic inflammatory myopathies have served to identify potentia
101 xamine if the muscle fibers in patients with inflammatory myopathies have the potential to behave as
102  and assessment tools to measure function in inflammatory myopathy have just recently emerged this de
103 ty complex upregulation, although typical of inflammatory myopathies, have been shown to occur in som
104 ) is the most common disabling, adult-onset, inflammatory myopathy histologically characterized by in
105 he requirements for an accurate diagnosis of inflammatory myopathy (i.e., polymyositis and dermatomyo
106 ed into six categories: (i) immobility, (ii) inflammatory myopathies, (iii) intensive care unit (ICU)
107                               The idiopathic inflammatory myopathies (IIM) continue to provide a chal
108 or other autoimmune diseases, the idiopathic inflammatory myopathies (IIM) develop as a result of spe
109                                   Idiopathic inflammatory myopathies (IIM) involve chronic inflammati
110                                   Idiopathic inflammatory myopathies (IIM), also known as myositis, a
111 with systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), and HLA-DQA1*0501 is a ri
112 , have not been developed for the idiopathic inflammatory myopathies (IIM), thus limiting our capacit
113 ignificant clinical challenges in idiopathic inflammatory myopathies (IIM).
114                                              Inflammatory myopathy (IIM) classification criteria have
115  clinical trials of patients with idiopathic inflammatory myopathy (IIM) has varied to date and over
116                       Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increa
117      The sequelae associated with idiopathic inflammatory myopathy (IIM) often result in disability a
118 ader on immunogenetic advances in idiopathic inflammatory myopathy (IIM) over the past 18 months.
119  American Caucasian patients with idiopathic inflammatory myopathy (IIM).
120 is but without silicone implants (idiopathic inflammatory myopathy; IIM patients).
121                               The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group
122                                   Idiopathic inflammatory myopathies (IIMs) are severe autoimmune dis
123                          Acquired immune and inflammatory myopathies (IIMs) are typically subdivided
124  we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to F
125 driving the autoimmune process in idiopathic inflammatory myopathies (IIMs) have not been unraveled,
126 understanding the genetics of the idiopathic inflammatory myopathies (IIMs) in the past 2 years, with
127 easing evidence suggests that the idiopathic inflammatory myopathies (IIMs) result from certain envir
128          This update on childhood idiopathic inflammatory myopathies (IIMs) reviews recent progress i
129                                   Idiopathic inflammatory myopathies (IIMs), or myositis, are rare di
130 e to the etiology of the juvenile idiopathic inflammatory myopathies (IIMs), which are systemic autoi
131 sions in patients with refractory idiopathic inflammatory myopathies (IIMs).
132 on and classification of acquired immune and inflammatory myopathies (IIMs).
133  dates in groups of patients with idiopathic inflammatory myopathies (IIMs).
134               Muscular dystrophies (MDs) and inflammatory myopathies (IMs) are debilitating skeletal
135 yositis is the most common of the idiopathic inflammatory myopathies in children.
136 l blood mononuclear cells from patients with inflammatory myopathies, in order to provide insight int
137          Evaluation of new therapies for the inflammatory myopathies is complicated by the heterogene
138 g inclusion body myositis from the other two inflammatory myopathies is the lack of responsiveness to
139 ng humoral characteristics of the idiopathic inflammatory myopathies is the specific targeting of com
140               The muscle microenvironment in inflammatory myopathy is complex.
141 atomyositis (JDM), the most common pediatric inflammatory myopathy, is a systemic vasculopathy affect
142 atomyositis (JDM), the most common pediatric inflammatory myopathy, is associated with significant mo
143   The childhood-onset or juvenile idiopathic inflammatory myopathies (JIIMs) are a heterogenous group
144 our understanding of the juvenile idiopathic inflammatory myopathies (JIIMs).
145 pha (TNF-alpha), a monokine overexpressed in inflammatory myopathies, led to a marked up-regulation o
146 al inflammatory myopathy (BCIM); histiocytic inflammatory myopathies, like sarcoid myopathy; and infl
147               Spontaneously occurring canine inflammatory myopathies may be good parallel disorders a
148 rstanding the role of mMyBP-C in this canine inflammatory myopathy may advance our knowledge of mecha
149 n the ability to diagnose several idiopathic inflammatory myopathy mimics.
150 of myopathy, including muscular dystrophies, inflammatory myopathies, mitochondrial/metabolic myopath
151 s successfully combated muscle wasting in an inflammatory myopathy model (cardiotoxin).
152 ealed none of these characteristics found in inflammatory myopathy muscle tissue.
153                                 In dogs with inflammatory myopathy, muscle-specific autoantibodies ha
154                         In contrast to other inflammatory myopathies, myositis-specific autoantibodie
155                     Patients with idiopathic inflammatory myopathies need to be managed in a multidis
156 phisticated agents for myasthenia gravis and inflammatory myopathies, neuroprotection with vitamin E
157   Juvenile dermatomyositis (DM) is a chronic inflammatory myopathy of childhood primarily affecting t
158 mmune disease and the most common idiopathic inflammatory myopathy of children.
159 inclusion body myositis (s-IBM) is a chronic inflammatory myopathy of unknown pathogenesis.
160 ercise intervention studies or in studies of inflammatory myopathies or muscle fibrosis, permitting g
161                               The idiopathic inflammatory myopathies or myositis syndromes (the most
162 n their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have ben
163 pus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or polyarteritis nodosa rather th
164  dermatomyositis and the juvenile idiopathic inflammatory myopathies over the past year included the
165 new findings implicate non-immune factors in inflammatory myopathy pathogenesis.
166 forefront in evaluating difficult idiopathic inflammatory myopathy patients.
167                                 In the human inflammatory myopathies (polymyositis and dermatomyositi
168 X activity in muscle fibres of patients with inflammatory myopathies provides useful prognostic infor
169  in systemic lupus erythematosus, idiopathic inflammatory myopathies, psoriasis, hidradenitis suppura
170 ology and much about the pathogenesis of the inflammatory myopathies remain a mystery.
171       The etiology and pathogenesis of human inflammatory myopathies remain unclear.
172  these molecules and the pathogenesis of the inflammatory myopathies remains obscure.
173                                       Canine inflammatory myopathies share clinical and histological
174  had muscle biopsy findings "consistent with inflammatory myopathy." She was referred to Johns Hopkin
175 the pathogenesis of muscular dystrophies and inflammatory myopathies shows complex interactions betwe
176         In patients with juvenile idiopathic inflammatory myopathy, stair-stepping exercise induces s
177 e distinguished from the commoner idiopathic inflammatory myopathies such as polymyositis and dermato
178 ment of chemokines in muscular dystrophy and inflammatory myopathies suggest that targeting specific
179 Our understanding of the pathogenesis of the inflammatory myopathies suggests an interplay between ad
180                         Recent literature in inflammatory myopathies suggests that both immune (cell-
181 ing systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, neuromyelitis
182 ids remain the mainstay of treatment for the inflammatory myopathies, their use is complicated by man
183 pected gene transcripts using microarrays in inflammatory myopathy tissue has led to the discovery of
184                               In the case of inflammatory myopathies, we have correctly identified th
185 ce of gene expression in the pathogenesis of inflammatory myopathies, we performed microarray experim
186 atomyositis (JDM), the most common pediatric inflammatory myopathy, weakness is accompanied by a char
187 nts of therapeutic strategies for idiopathic inflammatory myopathies were recently published.
188 nt discoveries about the pathogenesis of the inflammatory myopathies, which are not currently of prac
189 rmed in 19 patients with juvenile idiopathic inflammatory myopathy who performed stair-stepping exerc
190 or assessing target organs of the idiopathic inflammatory myopathies will likely evolve as more sensi
191 e the major epidemiological evidence linking inflammatory myopathies with cancer, and will use this e
192     Dermatomyositis is one of the idiopathic inflammatory myopathies with characteristic cutaneous ma
193 omyositis with vascular pathology from other inflammatory myopathies with skin changes that have prom
194 atory myopathies, like sarcoid myopathy; and inflammatory myopathies with vacuoles, aggregates and mi
195          Inclusion body myositis (IBM) is an inflammatory myopathy with distinctive clinicopathologic
196 lusion body myositis (sIBM) is an idiopathic inflammatory myopathy with invasion of CD8 T cells in mu
197 oradic inclusion body myositis, a late-onset inflammatory myopathy with prominent mitochondrial chang
198                                              Inflammatory myopathy, with muscle fiber invasion by leu

 
Page Top